Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on Aug 08, 2023 2:46pm
141 Views
Post# 35578054

RE:Here is how I see things

RE:Here is how I see thingsI agree with the part that this is an institution liquidating at any price.  But I am not too sure about the TH1902 part.  The trial still has not restarted.  It is extremely unlikely any results (that would give Marathon any assurances of the TH1902 trial eventually becoming a success) would come out before Oct 31st.   That is only 12 weeks away!!  Generally first scan for a patient would be after 6 weeks, and second scan 12 weeks.  And just because you are now dosing every 1 week doesn't change the scanning schedule.  So even if they has enrolled their first tomorrow that patient's second scan wouldn't come until after Oct 31st.  And that is just one patient, it wouldn't proof anything.  I believe the TH1902 trial is just a free lottery ticket for Marathon.

To me, more likely THTX has to either have $20 million on Oct 31 or least be moving in the right direction to get another extension.  And honestly, I don't know how THTX would be capable of doing this. Maybe by pausing the trial again and that is why we don't see if being restarted?


<< Previous
Bullboard Posts
Next >>